Idera and BioCryst Merge to Form Rare Disease Company

By Natasha Piper

Pharma Deals Review: Vol 2018 Issue 2 (Table of Contents)

Published: 1 Feb-2018

DOI: 10.3833/pdr.v2018.i2.2300     ISSN: 1756-7874

Section: Mergers & Acquisitions



BioCryst Pharmaceuticals and Idera Pharmaceuticals have entered into a definitive merger agreement to form a rare disease-focused company under a new name...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details